What question did this study set out to answer?

To evaluate the efficacy of brief and extended versions of digital AVATAR therapy combined with treatment as usual versus treatment as usual alone for reducing voice-related distress in people with psychosis.

October 28, 2024ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial

View Full Paper

Ask AI

Bookmark

Authors

PGPhilippa GaretyKing's College London CEClementine EdwardsKing's College London HJHassan JafariKing's College London

Discussion

Member takes

Overview

Randomized trial reveals digital AVATAR therapy reduces voice-related distress at 16 weeks in psychosis, suggesting extended protocols offer meaningful clinical benefits.

Key Points

To evaluate the efficacy of brief and extended versions of digital AVATAR therapy combined with treatment as usual versus treatment as usual alone for reducing voice-related distress in people with psychosis.
Randomized phase 2/3 trial (ISRCTN55682735) recruiting 345 participants with psychosis to compare AVATAR-Brief (AV-BRF) plus treatment as usual (TAU) and AVATAR-Extended (AV-EXT) plus TAU against TAU alone.
Conducted intention-to-treat analyses on primary outcomes (voice-related distress) and key secondary outcomes (voice severity and frequency) at 16 weeks (n=300) and 28 weeks (n=298).
Voice-related distress improved significantly at 16 weeks compared with TAU in both AV-BRF (effect -1.05 points, 96.5% CI = -2.110 to 0, P = 0.035, Cohen's d = 0.38) and AV-EXT (effect -1.60 points, 96.5% CI = -3.133 to -0.058, P = 0.029, Cohen's d = 0.58).
Distress improvements were not maintained at 28 weeks for AV-BRF (-0.62 points, 96.5% CI = -1.912 to 0.679, P = 0.316, Cohen's d = 0.22) or AV-EXT (-1.06 points, 96.5% CI = -2.700 to 0.586, P = 0.175, Cohen's d = 0.38).
Voice severity improved in both groups at 16 weeks but not at 28 weeks, voice frequency was significantly reduced only in AV-EXT across both time points, and no intervention-related serious adverse events occurred.

Cite This Study

Garety et al. (2024) studied this question.

synapsesocial.com/papers/69d838edf4e559c61eae2fcc https://doi.org/10.1038/s41591-024-03252-8

View Full Paper

Ask AI

Bookmark

October 28, 2024ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial

View Full Paper

Ask AI

Bookmark

Authors

PGPhilippa GaretyKing's College London CEClementine EdwardsKing's College London HJHassan JafariKing's College London

Discussion

Member takes

Overview

Randomized trial reveals digital AVATAR therapy reduces voice-related distress at 16 weeks in psychosis, suggesting extended protocols offer meaningful clinical benefits.

Key Points

To evaluate the efficacy of brief and extended versions of digital AVATAR therapy combined with treatment as usual versus treatment as usual alone for reducing voice-related distress in people with psychosis.
Randomized phase 2/3 trial (ISRCTN55682735) recruiting 345 participants with psychosis to compare AVATAR-Brief (AV-BRF) plus treatment as usual (TAU) and AVATAR-Extended (AV-EXT) plus TAU against TAU alone.
Conducted intention-to-treat analyses on primary outcomes (voice-related distress) and key secondary outcomes (voice severity and frequency) at 16 weeks (n=300) and 28 weeks (n=298).
Voice-related distress improved significantly at 16 weeks compared with TAU in both AV-BRF (effect -1.05 points, 96.5% CI = -2.110 to 0, P = 0.035, Cohen's d = 0.38) and AV-EXT (effect -1.60 points, 96.5% CI = -3.133 to -0.058, P = 0.029, Cohen's d = 0.58).
Distress improvements were not maintained at 28 weeks for AV-BRF (-0.62 points, 96.5% CI = -1.912 to 0.679, P = 0.316, Cohen's d = 0.22) or AV-EXT (-1.06 points, 96.5% CI = -2.700 to 0.586, P = 0.175, Cohen's d = 0.38).
Voice severity improved in both groups at 16 weeks but not at 28 weeks, voice frequency was significantly reduced only in AV-EXT across both time points, and no intervention-related serious adverse events occurred.

Cite This Study

Garety et al. (2024) studied this question.

synapsesocial.com/papers/69d838edf4e559c61eae2fcc https://doi.org/10.1038/s41591-024-03252-8

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark